Abstract
As the world continues to experience the COVID-19 pandemic, seasonal influenza remain a cause of severe morbidity and mortality globally. Worse yet, coinfection with SARS-CoV-2 and influenza A virus (IAV) leads to more severe clinical outcomes. The development of a combined vaccine against both COVID-19 and influenza is thus of high priority. Based on our established lipid nanoparticle (LNP)-encapsulated mRNA vaccine platform, we developed and characterized a novel mRNA vaccine encoding the HA antigen of influenza A (H1N1) virus, termed ARIAV. Then, ARIAV was combined with our COVID-19 mRNA vaccine ARCoV, which encodes the receptor-binding domain (RBD) of the SARS-CoV-2 S protein, to formulate the final combined vaccine, AR-CoV/IAV. Further characterization demonstrated that immunization with two doses of AR-CoV/IAV elicited robust protective antibodies as well as antigen-specific cellular immune responses against SARS-CoV-2 and IAV. More importantly, AR-CoV/IAV immunization protected mice from coinfection with IAV and the SARS-CoV-2 Alpha and Delta variants. Our results highlight the potential of the LNP-mRNA vaccine platform in preventing COVID-19 and influenza, as well as other respiratory diseases.
【초록키워드】 COVID-19, SARS-CoV-2, Vaccine, S protein, mRNA vaccine, Cellular immune response, Influenza, COVID-19 pandemic, influenza A virus, Delta, virus, influenza A, respiratory diseases, immunization, variants, clinical outcomes, Antigen, mice, RBD, H1N1, morbidity and mortality, vaccine platform, platform, Protective antibody, dose, Seasonal influenza, Final, ENCODE, IAV, highlight, robust, characterized, demonstrated, the receptor-binding domain, elicited, the SARS-CoV-2, 【제목키워드】 COVID-19, mRNA vaccine, Influenza,